Pharma News

University of Manchester researchers prove procalcitonin blood tests safely reduce antibiotic use in sepsis patients by two days, fighting resistance.

Merck & Co. explores a potential $28-$32 billion acquisition of Revolution Medicines to bolster its oncology pipeline with targeted RAS inhibitors.

UNC researchers discover a synergistic combination of TMZ and EdU that kills glioblastoma cells while sparing healthy tissue. A potential shift in brain cancer R&D.

Indonesia partners with WHO to expand clinical trial capacity. Learn about the 83% growth in research activity and the new 2026-2027 roadmap for global trials.

Exploring the FDA's 2025 reforms under HHS leadership. Will new pathways for PDCD and DCA lead to genuine deregulation or regulatory capture?

US FDA approves mitapivat (Aqvesme), the first oral pyruvate kinase activator for alpha- and beta-thalassemia. A breakthrough in treating chronic anemia.

Valneva terminates license agreement with Serum Institute of India (SII) to take direct control of Ixchiq chikungunya vaccine supply and commercialization.

BioAtla and GATC Health partner to advance Ozuriftamab vedotin (Oz-V) into Phase III trials for OPSCC. Explore the $40M SPV transaction and AI-driven drug discovery.

New Karolinska Institutet research shows GLP-1 agonists reduce dementia risk by 30%. Discover neuro-metabolic drug discovery targets at ChemDiv.

Hope Biosciences reports significant motor function gains in Parkinson’s Phase II trial for HB-adMSC stem cell therapy.

FDA grants approval for Mitapivat (Aqvesme) to treat anemia in adults with alpha- or beta-thalassemia. Explore clinical data.

Explore how patient-derived xenografts (PDX) and radiolabeled compounds are transforming radiopharmaceutical development, offering unparalleled insight into tumor biology for precision oncolog...